ICD-10-PCS Codes

• 1 3E06002 (INTRODUCTION OF HIGH-DOSE INTERLEUKIN-2 INTO CENTRAL ARTERY, OPEN APPROACH)

• 2 3E06003 (INTRODUCTION OF LOW-DOSE INTERLEUKIN-2 INTO CENTRAL ARTERY, OPEN APPROACH)

• 3 3E06005 (INTRODUCTION OF OTHER ANTINEOPLASTIC INTO CENTRAL ARTERY, OPEN APPROACH)

• 4 3E0600M (INTRODUCTION OF ANTINEOPLASTIC, MONOCLONAL ANTIBODY, INTO CENTRAL ARTERY, OPEN APPROACH)

• 5 3E0600P (INTRODUCTION OF CLOFARABINE INTO CENTRAL ARTERY, OPEN APPROACH)

• 6 3E06016 (INTRODUCTION OF RECOMBINANT HUMAN-ACTIVATED PROTEIN C INTO CENTRAL ARTERY, OPEN)

• 7 3E06017 (INTRODUCTION OF OTHER THROMBOLYTIC INTO CENTRAL ARTERY, OPEN APPROACH)

• 8 3E06028 (INTRODUCTION OF OXAZOLIDINONES INTO CENTRAL ARTERY, OPEN APPROACH)

• 9 3E06029 (INTRODUCTION OF OTHER ANTI-INFECTIVE INTO CENTRAL ARTERY, OPEN APPROACH)

• 10 3E0603Z (INTRODUCTION OF ANTI-INFLAMMATORY INTO CENTRAL ARTERY, OPEN APPROACH)

• 11 3E0604Z (INTRODUCTION OF SERUM, TOXOID AND VACCINE INTO CENTRAL ARTERY, OPEN APPROACH)

• 12 3E0606Z (INTRODUCTION OF NUTRITIONAL SUBSTANCE INTO CENTRAL ARTERY, OPEN APPROACH)

• 13 3E0607Z (INTRODUCTION OF ELECTROLYTIC AND WATER BALANCE SUBSTANCE INTO CENTRAL ARTERY, OPEN APPROACH)

• 14 3E060FZ (INTRODUCTION OF INTRACIRCULATORY ANESTHETIC INTO CENTRAL ARTERY, OPEN APPROACH)

• 15 3E060GC (INTRODUCTION OF OTHER THERAPEUTIC SUBSTANCE INTO CENTRAL ARTERY, OPEN APPROACH)

• 16 3E060GN (INTRODUCTION OF BLOOD BRAIN BARRIER DISRUPTION SUBSTANCE INTO CENTRAL ARTERY, OPEN APPROACH)

• 17 3E060HZ (INTRODUCTION OF RADIOACTIVE SUBSTANCE INTO CENTRAL ARTERY, OPEN APPROACH)

• 18 3E060KZ (INTRODUCTION OF OTHER DIAGNOSTIC SUBSTANCE INTO CENTRAL ARTERY, OPEN APPROACH)

• 19 3E060NZ (INTRODUCTION OF ANALGESICS, HYPNOTICS, SEDATIVES INTO CENTRAL ARTERY, OPEN APPROACH)

• 20 3E060PZ (INTRODUCTION OF PLATELET INHIBITOR INTO CENTRAL ARTERY, OPEN APPROACH)

• 21 3E060RZ (INTRODUCTION OF ANTIARRHYTHMIC INTO CENTRAL ARTERY, OPEN APPROACH)

• 22 3E060TZ (INTRODUCTION OF DESTRUCTIVE AGENT INTO CENTRAL ARTERY, OPEN APPROACH)

• 23 3E060VG (INTRODUCTION OF INSULIN INTO CENTRAL ARTERY, OPEN APPROACH)

• 24 3E060VH (INTRODUCTION OF HUMAN B-TYPE NATRIURETIC PEPTIDE INTO CENTRAL ARTERY, OPEN APPROACH)

• 25 3E060VJ (INTRODUCTION OF OTHER HORMONE INTO CENTRAL ARTERY, OPEN APPROACH)

• 26 3E060WK (INTRODUCTION OF IMMUNOSTIMULATOR INTO CENTRAL ARTERY, OPEN)

• 27 3E060WL (INTRODUCTION OF IMMUNOSUPPRESSIVE INTO CENTRAL ARTERY, OPEN)

• 28 3E060XZ (INTRODUCTION OF VASOPRESSOR INTO CENTRAL ARTERY, OPEN APPROACH)

• 29 3E06302 (INTRODUCTION OF HIGH-DOSE INTERLEUKIN-2 INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 30 3E06303 (INTRODUCTION OF LOW-DOSE INTERLEUKIN-2 INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 31 3E06305 (INTRODUCTION OF OTHER ANTINEOPLASTIC INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 32 3E0630M (INTRODUCTION OF ANTINEOPLASTIC, MONOCLONAL ANTIBODY, INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 33 3E0630P (INTRODUCTION OF CLOFARABINE INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 34 3E06316 (INTRODUCTION OF RECOMBINANT HUMAN-ACTIVATED PROTEIN C INTO CENTRAL ARTERY, PERCUTANEOUS)

• 35 3E06317 (INTRODUCTION OF OTHER THROMBOLYTIC INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 36 3E06328 (INTRODUCTION OF OXAZOLIDINONES INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 37 3E06329 (INTRODUCTION OF OTHER ANTI-INFECTIVE INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 38 3E0633Z (INTRODUCTION OF ANTI-INFLAMMATORY INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 39 3E0634Z (INTRODUCTION OF SERUM, TOXOID AND VACCINE INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 40 3E0636Z (INTRODUCTION OF NUTRITIONAL SUBSTANCE INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 41 3E0637Z (INTRODUCTION OF ELECTROLYTIC AND WATER BALANCE SUBSTANCE INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 42 3E063FZ (INTRODUCTION OF INTRACIRCULATORY ANESTHETIC INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 43 3E063GC (INTRODUCTION OF OTHER THERAPEUTIC SUBSTANCE INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 44 3E063GN (INTRODUCTION OF BLOOD BRAIN BARRIER DISRUPTION SUBSTANCE INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 45 3E063HZ (INTRODUCTION OF RADIOACTIVE SUBSTANCE INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 46 3E063KZ (INTRODUCTION OF OTHER DIAGNOSTIC SUBSTANCE INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 47 3E063NZ (INTRODUCTION OF ANALGESICS, HYPNOTICS, SEDATIVES INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 48 3E063PZ (INTRODUCTION OF PLATELET INHIBITOR INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 49 3E063RZ (INTRODUCTION OF ANTIARRHYTHMIC INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 50 3E063TZ (INTRODUCTION OF DESTRUCTIVE AGENT INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 51 3E063VG (INTRODUCTION OF INSULIN INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 52 3E063VH (INTRODUCTION OF HUMAN B-TYPE NATRIURETIC PEPTIDE INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 53 3E063VJ (INTRODUCTION OF OTHER HORMONE INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)

• 54 3E063WK (INTRODUCTION OF IMMUNOSTIMULATOR INTO CENTRAL ARTERY, PERCUTANEOUS)

• 55 3E063WL (INTRODUCTION OF IMMUNOSUPPRESSIVE INTO CENTRAL ARTERY, PERCUTANEOUS)

• 56 3E063XZ (INTRODUCTION OF VASOPRESSOR INTO CENTRAL ARTERY, PERCUTANEOUS APPROACH)